Vanguard Group Inc Akero Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,526,920 shares of AKRO stock, worth $245 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,526,920
Previous 4,529,628
0.06%
Holding current value
$245 Million
Previous $242 Million
11.07%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AKRO
# of Institutions
302Shares Held
91.5MCall Options Held
1.05MPut Options Held
388K-
Janus Henderson Group PLC London, X06.28MShares$340 Million0.14% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million9.63% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million3.48% of portfolio
-
Wellington Management Group LLP Boston, MA4.25MShares$230 Million0.04% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...